In October 2025, a publication in the International Journal of Molecular Sciences (doi:10.3390/ijms26209859) described Eutropics’ PRIMABS™ conformation‑specific antibody platform, which directly measures BCL‑2 family protein–protein interactions to predict response to BH3‑mimetics. Independent research groups are now citing this work in the context of BH3 profiling and functional precision oncology, underscoring PRIMABS™ potential as a clinically deployable companion diagnostic for apoptosis‑targeted therapies.
